share_log

一图读懂明巨诺-B(02126)2023年度业绩：收入同比增长19.3% 销售毛利率提升至50.7%

Read the 2023 results of Mingjuno-B (02126): Revenue increased 19.3% year-on-year, gross sales margin increased to 50.7%

Zhitong Finance ·  Mar 20 05:22

On March 20, Pharmaceutical Juno-B (02126) announced its annual results for the year ended December 31, 2023.

Zhitong Finance App learned that on March 20, Pharmaceutical Juno-B (02126) announced its annual results for the year ended December 31, 2023. The company achieved revenue of RMB 173.9 million during the period, an increase of 19.3% over the previous year. During the period, the company's gross profit increased sharply by 50.1% year on year, and gross sales margin increased to 50.7%. This increase is mainly due to the implementation of cost reduction plans and the achievement of economies of scale as more patients receive Benodat treatment.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment